Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Megan Othus

Showing results (91-100 of 232) with videos related to

Pageof 24
Sort By:
Cancer Medicine|July 25, 2020
Regimen-intensity per count-recovery and hospitalization index: A new tool to assign regimen intensity for AMLMohamed L Sorror, Shirali Agarwal, Megan Othus, et al.
Haematologica|August 4, 2022
Pulmonary function testing for fitness assessment in asymptomatic adults with newly diagnosed acute myeloid leukemiaRaffaele Palmieri, Megan Othus, Guang-Shing Cheng, et al.
British Journal of Haematology|March 4, 2014
SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemiaAnjali S Advani, Shannon McDonough, Steven Coutre, et al.
Bone Marrow Transplantation|August 29, 2024
Relationship between morphologic remission with or without hematologic recovery and outcome after allogeneic hematopoietic cell transplantation in adult acute myeloid leukemiaMegan Othus, Domitilla Baccon, Naveed Ali, et al.
Journal for Immunotherapy of Cancer|March 12, 2026
Evaluation of mixed response in tumor size and survival in patients with rare cancers treated with dual checkpoint inhibitor therapy (DART SWOG S1609)Young Kwang Chae, Megan Othus, Jiyon Lyu, et al.
Leukemia|July 31, 2023
Comparison between measurable residual disease relapse and morphologic relapse in acute myeloid leukemia and high-grade myeloid neoplasmsLauren Shih, Megan Othus, Kelda Schonhoff, et al.
Bone Marrow Transplantation|February 27, 2019
Pre-transplant bone marrow monocytic myeloid-derived suppressor cell frequency is not associated with outcome after allogeneic hematopoietic cell transplantation for acute myeloid leukemia in remissionColin D Godwin, Jonathan R Fromm, Megan Othus, et al.
Blood|January 28, 2021
Acute myeloid leukemia measurable residual disease detection by flow cytometry in peripheral blood vs bone marrowColin D Godwin, Yi Zhou, Megan Othus, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 10, 2012
Randomized phase II trial of sorafenib with temsirolimus or tipifarnib in untreated metastatic melanoma (S0438)Kim A Margolin, James Moon, Lawrence E Flaherty, et al.
Leukemia & Lymphoma|December 21, 2020
Comparison of myeloid blast counts and variant allele frequencies of gene mutations in myelodysplastic syndrome with excess blasts and secondary acute myeloid leukemiaXueyan Chen, Megan Othus, Brent L Wood, et al.
Pageof 24

Showing results (91-100 of 232) with videos related to

Sort By:
Pageof 24
Cancer Medicine|July 25, 2020
Regimen-intensity per count-recovery and hospitalization index: A new tool to assign regimen intensity for AMLMohamed L Sorror, Shirali Agarwal, Megan Othus, et al.
Haematologica|August 4, 2022
Pulmonary function testing for fitness assessment in asymptomatic adults with newly diagnosed acute myeloid leukemiaRaffaele Palmieri, Megan Othus, Guang-Shing Cheng, et al.
British Journal of Haematology|March 4, 2014
SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemiaAnjali S Advani, Shannon McDonough, Steven Coutre, et al.
Bone Marrow Transplantation|August 29, 2024
Relationship between morphologic remission with or without hematologic recovery and outcome after allogeneic hematopoietic cell transplantation in adult acute myeloid leukemiaMegan Othus, Domitilla Baccon, Naveed Ali, et al.
Journal for Immunotherapy of Cancer|March 12, 2026
Evaluation of mixed response in tumor size and survival in patients with rare cancers treated with dual checkpoint inhibitor therapy (DART SWOG S1609)Young Kwang Chae, Megan Othus, Jiyon Lyu, et al.
Leukemia|July 31, 2023
Comparison between measurable residual disease relapse and morphologic relapse in acute myeloid leukemia and high-grade myeloid neoplasmsLauren Shih, Megan Othus, Kelda Schonhoff, et al.
Bone Marrow Transplantation|February 27, 2019
Pre-transplant bone marrow monocytic myeloid-derived suppressor cell frequency is not associated with outcome after allogeneic hematopoietic cell transplantation for acute myeloid leukemia in remissionColin D Godwin, Jonathan R Fromm, Megan Othus, et al.
Blood|January 28, 2021
Acute myeloid leukemia measurable residual disease detection by flow cytometry in peripheral blood vs bone marrowColin D Godwin, Yi Zhou, Megan Othus, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 10, 2012
Randomized phase II trial of sorafenib with temsirolimus or tipifarnib in untreated metastatic melanoma (S0438)Kim A Margolin, James Moon, Lawrence E Flaherty, et al.
Leukemia & Lymphoma|December 21, 2020
Comparison of myeloid blast counts and variant allele frequencies of gene mutations in myelodysplastic syndrome with excess blasts and secondary acute myeloid leukemiaXueyan Chen, Megan Othus, Brent L Wood, et al.
Pageof 24